Compare ImmunityBio Inc. Common Stock (IBRX) vs WEC Energy Group Inc. Common Stock (WEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ImmunityBio Inc. Common Stock vs WEC Energy Group Inc. Common Stock — how do they compare? ImmunityBio Inc. Common Stock trades at $9.99 (market cap $10.39B), while WEC Energy Group Inc. Common Stock trades at $107 (market cap $34.50B). The key difference: WEC Energy Group Inc. Common Stock is far larger — about 3.3× ImmunityBio Inc. Common Stock's market cap, and WEC Energy Group Inc. Common Stock pays a 3.6% dividend while ImmunityBio Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold ImmunityBio Inc. Common Stock for 6 Days and WEC Energy Group Inc. Common Stock for 0 Days on average.
| IBRX | WEC | |
|---|---|---|
Market Cap | $10.39B | $34.50B |
Volume | 11,509,049 | 2,835,735 |
Sector | Health | Utilities |
52-Week High | $11.55 | $118.85 |
52-Week Low | $1.98 | $100.78 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $10.84B | $57.46B |
Dividend Yield | — | 3.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ImmunityBio (IBRX) trades at $9.80, down 3.16% on the day, amid a bullish technical setup and strong analyst support. The company reported revenue growth to $166 million in 2026 but remains deeply unprofitable with a net loss of $992 million. Recent FDA approval expansion for ANKTIVA in bladder cancer and high-profile executive appointments signal operational momentum, though cash burn remains a concern with negative operating cash flow.
Outlook is cautiously optimistic given the unanimous buy ratings and regulatory milestones, but investment carries high risk due to persistent losses, heavy reliance on financing, and competitive pressures. The stock's trajectory hinges on successful commercialization and pipeline execution to achieve profitability.
WEC Energy Group trades at $105.87, up 0.92% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q2 2026 EPS of $0.91 vs. $0.804 expected) and improving profitability (net margin 16.7%). Recent news highlights growing data center demand as a key growth driver, with the company engaging in large-scale customer discussions for 400-500 megawatt projects.
WEC presents a compelling utility investment with stable cash flows and dividend potential, though faces interest rate sensitivity. Analyst consensus targets $118.33 (12% upside) with majority Hold ratings. Key risks include regulatory pressures and capital expenditure requirements for infrastructure expansion through 2030.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ImmunityBio Inc. Common Stock
ImmunityBio develops immune-based therapies for cancer and infectious diseases. Its programs are designed to activate and strengthen the body’s immune response.
Read more on IBRX →About WEC Energy Group Inc. Common Stock
WEC Energy Group is a Midwest electric and natural gas utility holding company whose subsidiaries, including We Energies and Wisconsin Public Service, deliver electricity and natural gas to customers in Wisconsin, Illinois, Michigan, and Minnesota.
Read more on WEC →
